CIK 0001831363
TERN Terns Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Jun 25, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Signals
Open-market buys and sells at Terns Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 44Moderate | Amy L. Burroughs Chief Executive Officer buy | $90k 23,314 shares | +98% | - | |
| 33Weak | Amy L. Burroughs Chief Executive Officer buy | $2,606 510 shares | +3% | - | |
| 31Weak | Melita Sun Jung Chief Business Officer buy | $11k 2,250 shares | - | - | |
| 20Weak | Emil Kuriakose Chief Medical Officer sell | $26k 4,481 shares | -8% | - | |
| 58Moderate | Amy L. Burroughs Chief Executive Officer buy | $110k 15,450 shares | +423% | - |
Transactions
The last 14 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2025 | Amy L. Burroughs Chief Executive Officer | POpen-market purchase Common Stock | +23,314 | $3.87 | $90k | 47,083 | Jun 25, 2025 |
| Feb 24, 2025 | Andrew Gengos Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +750,000 | $0.00 | $0 | 750,000 | Feb 25, 2025 |
| Feb 20, 2025 | Robert Azelby director | AGrant or award Stock Option (Right to Buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Feb 24, 2025 |
| Feb 1, 2025 | David A Fellows director | AGrant or award Stock Option (Right to Buy)derivative | +18,650 | $0.00 | $0 | 18,650 | Feb 3, 2025 |
| Feb 1, 2025 | Jeffrey B Kindler director | AGrant or award Stock Option (Right to Buy)derivative | +10,657 | $0.00 | $0 | 10,657 | Feb 3, 2025 |
| Jan 30, 2025 | Emil Kuriakose Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +485,000 | $0.00 | $0 | 485,000 | Feb 3, 2025 |
| Nov 30, 2024 | Amy L. Burroughs Chief Executive Officer | POpen-market purchase Common Stock | +510 | $5.11 | $2,606 | 19,609 | Feb 3, 2025 |
| Nov 30, 2024 | Melita Sun Jung Chief Business Officer | POpen-market purchase Common Stock | +2,250 | $5.11 | $11k | 2,250 | Feb 3, 2025 |
| Jan 30, 2025 | Amy L. Burroughs Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +1,075,000 | $0.00 | $0 | 1,075,000 | Feb 3, 2025 |
| Jan 30, 2025 | Melita Sun Jung Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +325,000 | $0.00 | $0 | 325,000 | Feb 3, 2025 |
| Jan 2, 2025 | Emil Kuriakose Chief Medical Officer | SOpen-market sale Common Stock | -4,481 | $5.71 | $26k | 54,269 | Jan 6, 2025 |
| Dec 12, 2024 | Emil Kuriakose Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Dec 16, 2024 |
| Dec 5, 2024 | Amy L. Burroughs Chief Executive Officer | POpen-market purchase Common Stock | +15,450 | $7.15 | $110k | 19,099 | Dec 9, 2024 |
| Nov 18, 2024 | Heather D Turner director | AGrant or award Stock Option (Right to Buy)derivative | +64,000 | $0.00 | $0 | 64,000 | Nov 19, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Robert Azelbydirector
- Amy L. BurroughsChief Executive Officer
- David A Fellowsdirector
- Andrew GengosChief Financial Officer
- Melita Sun JungChief Business Officer
- Jeffrey B Kindlerdirector
- Emil KuriakoseChief Medical Officer
- Heather D Turnerdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.